CEO
Lynx Biosciences, Inc., California, United States
Dr. Chorom Pak launched Lynx Biosciences, Inc. (LynxBio) to commercialize MicroC3™, a multi-omic microfluidic platform developed while earning her PhD in Molecular and Cellular Pharmacology from the University of Wisconsin – Madison. The technology was born out of an interdisciplinary collaboration between cancer biologists, physicians, biomedical engineers, physicists, and biostatisticians to solve the technical challenge of characterizing suspension cells in a miniaturized manner that would recapitulate individual patients’ disease. LynxBio is partnered with multiple pharmaceutical companies to leverage the MicroC3™ technology for immuno-oncology drug discovery and development. Before creating LynxBio, Chorom was the clinical and R&D lead at Cellectar Biosciences, Inc. (NASDAQ:CLRB), where she co-developed a drug against hematological malignancies and advanced it to Phase 2 clinical trials. Dr. Pak was awarded the Biocom Catalyst Award, holds seven patents, and has over 13 years of experience with hematological cancers and development of microfluidic platforms.
Disclosure information not submitted.
Wednesday, February 9, 2022
10:30 AM – 11:00 AM